ArticleAntimicrobial agents and chemotherapy1995
Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation.
Article in Antimicrobial agents and chemotherapy, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 82 citations in OpenAlex.
- Chemogenomic Profiling of the Fungal Pathogen Candida albicans.Antimicrobial agents and chemotherapy · 2018Article
- A prototype antifungal contact lens.Investigative ophthalmology & visual science · 2011Article
- Updating corneofungimetry: a bioassay exploring dermatomycoses and antifungal susceptibility.Mycopathologia · 2010Review
- One year prospective survey of Candida bloodstream infections in Scotland.Journal of medical microbiology · 2007Article
- Population structure and properties of Candida albicans, as determined by multilocus sequence typing.Journal of clinical microbiology · 2005Article
- In vitro and in vivo activities of the novel azole antifungal agent r126638.Antimicrobial agents and chemotherapy · 2004Article
- Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species.Antimicrobial agents and chemotherapy · 2002Article
- Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates.Antimicrobial agents and chemotherapy · 2002Article
- Antifungal susceptibility testing: practical aspects and current challenges.Clinical microbiology reviews · 2001Review
- Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp.Journal of clinical microbiology · 2001Article
- Comparison of three methods of determining MICs for filamentous fungi using different end point criteria and incubation periods.Antimicrobial agents and chemotherapy · 2000Article
- Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose.Antimicrobial agents and chemotherapy · 2000Article
- Accumulation of 3-ketosteroids induced by itraconazole in azole-resistant clinical Candida albicans isolates.Antimicrobial agents and chemotherapy · 1999Article
- Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility.Journal of clinical microbiology · 1999Article
- The spheroplast lysis assay for yeast in microtiter plate format.Applied and environmental microbiology · 1999Article
- Influence of incubation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole.Journal of clinical microbiology · 1999Article
- Optimisation of itraconazole therapy using target drug concentrations.Clinical pharmacokinetics · 1998Review
- Prevalence of Candida dubliniensis isolates in a yeast stock collection.Journal of clinical microbiology · 1998Article
- Molecular biological characterization of an azole-resistant Candida glabrata isolate.Antimicrobial agents and chemotherapy · 1997Article
- Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes.Antimicrobial agents and chemotherapy · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The technical parameters for antifungal susceptibility testing with Candida species were reexamined to determine the optimal conditions for testing with semiautomated preparations of broth microdilution cultures, automated spectrophotometric readings of the cultures, and dose-response and endpoint determinations by means of a computer spreadsheet. Tests were based on proposed standard method M27P of the National Committee for Clinical Laboratory Standards for antifungal agents. RPMI 1640 broth with extra glucose to a final concentration of 2% gave higher and more reproducible drug-free control readings without affecting susceptibility endpoint readings. An inoculum of 8 x 10(4) yeasts per ml prepared from a carbon-limiting broth culture without further standardization was found to give optimal control readings after 48 h of incubation at 37 degrees C. For flucytosine, fluconazole, itraconazole, and ketoconazole, endpoints based on 50% growth inhibition (50% inhibitory concentration) gave the minimum variation with inoculum size and the fewest endpoint differences with RPMI 1640 medium obtained from two different suppliers. The 50% inhibitory concentration was also the optimal endpoint for fluconazole and ketoconazole susceptibilities in comparison with broth macrodilution MICs determined by the method of the National Committee for Clinical Laboratory Standards. Intralaboratory reproducibility was determined by retrospective analysis of replicate results for isolates retested at random over a 2-year period. This approach showed less favorable reproducibility than has been reported from purpose-designed, prospective antifungal susceptibility studies, but it may better reflect real-life test reproducibility. Susceptibility data for 616 clinical isolates of yeasts, representing 16 Candida and Saccharomyces spp., confirmed the tendency of Candida lusitaniae isolates to show relatively low susceptibilities to amphotericin B, the tendency of Candida krusei isolates to show low flucytosine and fluconazole susceptibilities, and the presence of some isolates in the species Candida albicans, Candida glabrata, and Candida tropicalis with low susceptibilities to azole derivative antifungal agents. The study demonstrates the value of automation and standardization in all stages of yeast susceptibility testing, from plate preparation to data analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.